Compare AbbVie Inc (ABBV) vs iShares Core Growth Allocation ETF (AOR) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

AOR, the iShares Core Growth Allocation ETF, trades at $70.12, up 0.57% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a fixed 60/40 stock/bond allocation, rebalances semiannually, and offers low-cost exposure with a 0.20% fee. Recent news highlights its role as a core holding but notes long-term underperformance versus the S&P 500 over the past decade.

The outlook for AOR hinges on its diversified asset allocation strategy providing stability, though it faces risks from equity and fixed income market volatility. Its simplicity appeals to investors seeking a hands-off approach, but competition from pure equity funds and interest rate sensitivity are key considerations for potential returns.